Corrigendum to “Efficient gene delivery to photoreceptors using AAV2/rh10 and rescue of the Rho–/– mouse” (Molecular Therapy - Methods and Clinical Development (2015) 2 (S2329050116300286) (10.1038/mtm.2015.16));Efficient gene delivery to photoreceptors using AAV2/rh10 and rescue of the Rho−/− mouse

Molecular Therapy Methods and Clinical Development

Volumn 2, Issue , 2015, Pages 15016-

  Palfi, Arpad ^a   Chadderton, Naomi ^a   O'Reilly, Mary ^a   Nagel Wolfrum, Kerstin ^b   Wolfrum, Uwe ^b   Bennett, Jean ^c   Humphries, Peter ^a   Kenna, Paul ^a   Millington Ward, Sophia ^a   Farrar, Jane ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; MESSENGER RNA; RHODOPSIN; BETA ACTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTRORETINOGRAPHY; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; MOUSE; NONHUMAN; PHOTORECEPTOR; PHOTORECEPTOR INNER SEGMENT; PRIORITY JOURNAL; RETINA DEGENERATION; RETINAL ROD OUTER SEGMENT; SEROTYPE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ADULT; ANTIBODY LABELING; ELECTRON MICROSCOPY; ELECTRORETINOGRAM; GENE EXPRESSION; GENETIC TRANSDUCTION; NEWBORN; OPTOMETRY; PHOTORECEPTOR CELL; PROMOTER REGION; REVERSE TRANSCRIPTION LOOP MEDIATED ISOTHERMAL AMPLIFICATION; SUBRETINAL DRUG ADMINISTRATION; TRANSGENE;

EID: 85015258377     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2016.32     Document Type: Erratum

References (46)

1. 1 Bainbridge, JW, Smith, AJ, Barker, SS, Robbie, S, Henderson, R, Balaggan, K, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358 (2008), 2231–2239.
2. 2 Maguire, AM, Simonelli, F, Pierce, EA, Pugh, EN Jr, Mingozzi, F, Bennicelli, J, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358 (2008), 2240–2248.
3. 3 Hauswirth, W, Aleman, TS, Kaushal, S, Cideciyan, AV, Schwartz, SB, Wang, L, et al. Phase I trial of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results. Hum Gene Ther 19 (2008), 979–990.
4. 4 Bennett, J, Immune response following intraocular delivery of recombinant viral vectors. Gene Ther 10 (2003), 977–982.
5. 5 Willett, K, Bennett, J, Immunology of AAV-mediated gene transfer in the eye. Front Immunol, 4, 2013, 261.
6. 6 MacLaren, RE, Groppe, M, Barnard, AR, Cottriall, CL, Tolmachova, T, Seymour, L, et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase ½ clinical trial. Lancet 383 (2014), 1129–1137.
7. 7 Auricchio, A, Kobinger, G, Anand, V, Hildinger, M, O'Connor, E, Maguire, AM, et al. Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum Mol Genet 10 (2001), 3075–3081.
8. 8 Rabinowitz, JE, Rolling, F, Li, C, Conrath, H, Xiao, W, Xiao, X, et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 76 (2002), 791–801.
9. 9 Gao, G, Wilson, JM, Alvira, A, Adeno-associated virus (AAV) serotype rh10. European Patent EP2341068B1, 2002.
10. 10 Gao, GP, Alvira, MR, Wang, L, Calcedo, R, Johnston, J, Wilson, JM, Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 99 (2002), 11854–11859.
11. 11 Maheshri, N, Koerber, JT, Kaspar, BK, Schaffer, DV, Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol 24 (2006), 198–204.
12. 12 Koerber, JT, Jang, JH, Schaffer, DV, DNA shuffling of adeno-associated virus yields functionally diverse viral progeny. Mol Ther 16 (2008), 1703–1709.
13. 13 Lebherz, C, Maguire, A, Tang, W, Bennett, J, Wilson, JM, Novel AAV serotypes for improved ocular gene transfer. J Gene Med 10 (2008), 375–382.
14. 14 Koerber, JT, Klimczak, R, Jang, JH, Dalkara, D, Flannery, JG, Schaffer, DV, Molecular evolution of adeno-associated virus for enhanced glial gene delivery. Mol Ther 17 (2009), 2088–2095.
15. 15 Dalkara, D, Byrne, LC, Klimczak, RR, Visel, M, Yin, L, Merigan, WH, et al. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med, 5, 2013, 189ra76.
16. 16 Cronin, T, Vandenberghe, LH, Hantz, P, Juttner, J, Reimann, A, Kacsó, AE, et al. Efficient transduction and optogenetic stimulation of retinal bipolar cells by a synthetic adeno-associated virus capsid and promoter. EMBO Mol Med 6 (2014), 1175–1190.
17. 17 Zinn, E, Vandenberghe, LH, Adeno-associated virus: fit to serve. Curr Opin Virol 8 (2014), 90–97.
18. 18 Reich, SJ, Auricchio, A, Hildinger, M, Glover, E, Maguire, AM, Wilson, JM, et al. Efficient trans-splicing in the retina expands the utility of adeno-associated virus as a vector for gene therapy. Hum Gene Ther 14 (2003), 37–44.
19. 19 Surace, EM, Auricchio, A, Reich, SJ, Rex, T, Glover, E, Pineles, S, et al. Delivery of adeno-associated virus vectors to the fetal retina: impact of viral capsid proteins on retinal neuronal progenitor transduction. J Virol 77 (2003), 7957–7963.
20. 20 Watanabe, S, Sanuki, R, Ueno, S, Koyasu, T, Hasegawa, T, Furukawa, T, Tropisms of AAV for subretinal delivery to the neonatal mouse retina and its application for in vivo rescue of developmental photoreceptor disorders. PLoS One, 8, 2013, e54146.
21. 21 Bruewer, AR, Mowat, FM, Bartoe, JT, Boye, SL, Hauswirth, WW, Petersen-Jones, SM, Evaluation of lateral spread of transgene expression following subretinal AAV-mediated gene delivery in dogs. PLoS One, 8, 2013, e60218.
22. 22 Allocca, M, Mussolino, C, Garcia-Hoyos, M, Sanges, D, Iodice, C, Petrillo, M, et al. Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors. J Virol 81 (2007), 11372–11380.
23. 23 Cearley, CN, Wolfe, JH, Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9 and Rh10 in the mouse brain. Mol Ther 13 (2006), 528–537.
24. 24 Hu, C, Busuttil, RW, Lipshutz, GS, RH10 provides superior transgene expression in mice when compared with natural AAV serotypes for neonatal gene therapy. J Gene Med 12 (2010), 766–778.
25. 25 Sondhi, D, Johnson, L, Purpura, K, Monette, S, Souweidane, MM, Kaplitt, MG, et al. Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis. Hum Gene Ther Methods 23 (2012), 324–335.
26. 26 Giove, TJ, Sena-Esteves, M, Eldred, WD, Transduction of the inner mouse retina using AAVrh8 and AAVrh10 via intravitreal injection. Exp Eye Res 91 (2010), 652–659.
27. 27 Mao, Y, Kiss, S, Boyer, JL, Hackett, NR, Qiu, J, Carbone, A, et al. Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab. Hum Gene Ther 22 (2011), 1525–1535.
28. 28 Humphries, MM, Rancourt, D, Farrar, GJ, Kenna, P, Hazel, M, Bush, RA, et al. Retinopathy induced in mice by targeted disruption of the rhodopsin gene. Nat Genet 15 (1997), 216–219.
29. 29 Palfi, A, Millington-Ward, S, Chadderton, N, O'Reilly, M, Goldmann, T, Humphries, MM, et al. Adeno-associated virus-mediated rhodopsin replacement provides therapeutic benefit in mice with a targeted disruption of the rhodopsin gene. Hum Gene Ther 21 (2010), 311–323.
30. 30 Olsson, JE, Gordon, JW, Pawlyk, BS, Roof, D, Hayes, A, Molday, RS, et al. Transgenic mice with a rhodopsin mutation (Pro23His): a mouse model of autosomal dominant retinitis pigmentosa. Neuron 9 (1992), 815–830.
31. 31 Douglas, RM, Alam, NM, Silver, BD, McGill, TJ, Tschetter, WW, Prusky, GT, Independent visual threshold measurements in the two eyes of freely moving rats and mice using a virtual-reality optokinetic system. Vis Neurosci 22 (2005), 677–684.
32. 32 Yang, B, Li, S, Wang, H, Guo, Y, Gessler, DJ, Cao, C, et al. Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10. Mol Ther 22 (2014), 1299–1309.
33. 33 O'Reilly, M, Millington-Ward, S, Palfi, A, Chadderton, N, Cronin, T, McNally, N, et al. A transgenic mouse model for gene therapy of rhodopsin-linked retinitis pigmentosa. Vision Res 48 (2008), 386–391.
34. 34 Cideciyan, AV, Jacobson, SG, Beltran, WA, Sumaroka, A, Swider, M, Iwabe, S, et al. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci USA 110 (2013), E517–E525.
35. 35 Tardieu, M, Zérah, M, Husson, B, de Bournonville, S, Deiva, K, Adamsbaum, C, et al. Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial. Hum Gene Ther 25 (2014), 506–516.
36. 36 Crystal, RG, Bethesda, MD, Recombinant DNA Advisory Committee, National Institutes of Health, 2009.
37. 37 Ferreira, V, Twisk, J, Kwikkers, K, Aronica, E, Brisson, D, Methot, J, et al. Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy. Hum Gene Ther 25 (2014), 180–188.
38. 38 Testa, F, Maguire, AM, Rossi, S, Pierce, EA, Melillo, P, Marshall, K, et al. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology 120 (2013), 1283–1291.
39. 39 Farrar, GJ, Millington-Ward, S, Chadderton, N, Mansergh, FC, Palfi, A, Gene therapies for inherited retinal disorders. Vis Neurosci 31 (2014), 289–307.
40. 40 Swain, GP, Prociuk, M, Bagel, JH, O'Donnell, P, Berger, K, Drobatz, K, et al. Adeno-associated virus serotypes 9 and rh10 mediate strong neuronal transduction of the dog brain. Gene Ther 21 (2014), 28–36.
41. 41 Holehonnur, R, Luong, JA, Chaturvedi, D, Ho, A, Lella, SK, Hosek, MP, et al. Adeno-associated viral serotypes produce differing titers and differentially transduce neurons within the rat basal and lateral amygdala. BMC Neurosci, 15, 2014, 28.
42. 42 Rohr, UP, Wulf, MA, Stahn, S, Steidl, U, Haas, R, Kronenwett, R, Fast and reliable titration of recombinant adeno-associated virus type-2 using quantitative real-time PCR. J Virol Methods 106 (2002), 81–88.
43. 43 Matsuda, T, Cepko, CL, Electroporation and RNA interference in the rodent retina in vivo and in vitro. Proc Natl Acad Sci USA 101 (2004), 16–22.
44. 44 Chadderton, N, Millington-Ward, S, Palfi, A, O'Reilly, M, Tuohy, G, Humphries, MM, et al. Improved retinal function in a mouse model of dominant retinitis pigmentosa following AAV-delivered gene therapy. Mol Ther 17 (2009), 593–599.
45. 45 Kiang, AS, Palfi, A, Ader, M, Kenna, PF, Millington-Ward, S, Clark, G, et al. Toward a gene therapy for dominant disease: validation of an RNA interference-based mutation-independent approach. Mol Ther 12 (2005), 555–561.
46. 46 Chadderton, N, Palfi, A, Millington-Ward, S, Gobbo, O, Overlack, N, Carrigan, M, et al. Intravitreal delivery of AAV-NDI1 provides functional benefit in a murine model of Leber hereditary optic neuropathy. Eur J Hum Genet 21 (2013), 62–68.